Percheron Therapeutics, previously known as Antisense, has appointed biotech executive Dr Michael Baker as its new chief executive officer and managing director, as current CEO Dr James Garner prepares to leave the role for an overseas opportunity. …
Percheron turns to former Arovella chief Michael Baker for next phase of HMBD 002 development
August 10, 2026 Latest NewsAustralian BiotechBioPharmaDispatch Executive
Latest Video
New Stories
-
ENA Respiratory secures funding to test antiviral nasal spray in people with asthma
September 2, 2026 - -
OncoSil pursues a reimbursement pathway as it prepares for US rollout
September 2, 2026 - - Australian Biotech -
Vitrafy takes its cryopreservation technology into the US cell therapy market
September 2, 2026 - - Australian Biotech -
Telix completes BiPASS enrolment as it pursues a broader role for PSMA PET
September 2, 2026 - - Australian Biotech -
Roche maps a new chapter with move to new Sydney CBD location
September 2, 2026 - - Latest News -
Priceline Pharmacy broadens women’s health support with new parenting program
September 2, 2026 - -
The non-disclosure agreement is just about creating a zone of controlled silence
September 2, 2026 -